The main therapeutic aim in severe Falciparum malaria is to clear the initial parasitaemia. A rapidly acting schizontocidal drug such as quinine to which there may be partial resistance is preferable to a slow acting drug to which resistance has not been reported. In complicated cases however, a slow acting drug for example sulphadoxine-pyrimethamine (Fansidar) would be indicated because speed of action is less important than prevention of recrudesence. Patients treated with drugs to which their parasites are partially resistant may appear to be clinically cured.